Alex Azrilevich

Alex has served as Synthekine’s Vice President of Clinical Development since December 2021. Alex joined Synthekine following 13 years at Bristol Myers Squibb, where he most recently led the development of next-generation CTLA-4 assets as Executive Director, Early Development Program Lead. During his time at Bristol Myers Squibb, Alex oversaw the development of over 10 oncology assets at various stages of development, including Ph1/2/3, health authority filings and approvals, and medical affairs. Among his accomplishments, Alex led programs through successful IND submission, guided early-phase study teams through multiple Go/No Go decisions, and built a successful bladder cancer program in late development, resulting in meaningful practice changes in advanced and adjuvant bladder cancer. Alex completed a Pharmaceutical Industry Fellowship at Rutgers University and received his PharmD at Temple University School of Pharmacy.